Navigation Links
New compound holds promise for treating Duchenne MD, other inherited diseases
Date:6/27/2012

Scientists at UCLA have identified a new compound that could treat certain types of genetic disorders in muscles. It is a big first step in what they hope will lead to human clinical trials for Duchenne muscular dystrophy.

Duchenne muscular dystrophy, or DMD, is a degenerative muscle disease that affects boys almost exclusively. It involves the progressive degeneration of voluntary and cardiac muscles, severely limiting the life span of sufferers.

In a new study, senior author Carmen Bertoni, an assistant professor in the UCLA Department of Neurology, first author Refik Kayali, a postgraduate fellow in Bertoni's lab, and their colleagues demonstrate the efficacy of a new compound known as RTC13, which suppresses so-called "nonsense" mutations in a mouse model of DMD.

The findings appear in the current online edition of the journal Human Molecular Genetics.

"We are excited about these new findings because they represent a major step toward the development of a drug that could potentially treat this devastating disease in humans," Bertoni said. "We knew that the compounds were effective in cells isolated from the mouse model for DMD, but we did not know how they would behave when administered in a living organism."

Nonsense mutations are generally caused by a single change in DNA that disrupts the normal cascade of events that changes a gene into messenger RNA, then into a protein. The result is a non-functioning protein. Approximately 13 percent of genetic defects known to cause diseases are due to such mutations. In the case of DMD, the "missing" protein is called dystrophin.

For the study, Bertoni and Kayali collaborated with the laboratory of Dr. Richard Gatti, a professor of pathology and laboratory medicine and of human genetics at UCLA. Working with the UCLA Molecular Shared Screening Resource facility at the campus's California NanoSystems Institute, the Gatti lab screened some 35,000
'/>"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nonstoichiometric Compounds V - An ECI Conference Series
2. New drug-screening method yields long-sought anti-HIV compounds
3. Dont feel like exercise? Scientists find compound that may help you work out harder
4. Nuisance seaweed found to produce compounds with biomedical potential
5. Like curry? New biological role identified for compound used in ancient medicine
6. Heparin-like compounds inhibit breast cancer metastasis to bone
7. Sulphur and iron compounds common in old shipwrecks
8. New screening technique yields elusive compounds to block immune-regulating enzyme
9. Biosensor illuminates compounds to aid fight against TB
10. Canadian girl, 16, invents disease-fighting, anti-aging compound using tree particles
11. Remote Siberian lake holds clues to Arctic -- and Antarctic -- climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... 5, 2014 – University of Utah engineers developed the ... jet fuel produce electricity without needing to ignite the ... power portable electronics, off-grid power and sensors. , A ... the American Chemical Society journal ACS Catalysis . ... chemical reaction between a fuel and an oxygen-rich source ...
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... mother,s iron deficiency early in pregnancy may have a profound ... even if the lack of iron is not enough to ... Center study published in the scientific journal PLoS One ... notice or treat mild or moderate iron deficiency, and therefore ...
... COLD SPRING HARBOR, N.Y. (March 22, 2011) - ... both to scientists and nonscientists alike. Its behavior involves ... as those external to itenvironment and social surroundings. According ... the tapestry of biology: It is sparked when neurons ...
... years, researchers have worked to develop more flexible, functional ... or Iraq with missing arms or legs. But even ... body through the space where the device has been ... the bacteria would enter the body, and that,s where ...
Cached Biology News:Pre-conception and early pregnancy iron deficiency harms brain 2Pre-conception and early pregnancy iron deficiency harms brain 3New book on animal behavior provides integrated view 2Nanomodified surfaces seal leg implants against infection 2
(Date:11/21/2014)... (PRWEB) November 20, 2014 ... (XNA, Chassis, Oligos, Enzymes, Cloning kits), Technology ... Application (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global ... major market drivers, threats, opportunities, and challenges. ... 46 figures spread through 185 pages and ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 2014 ... Ferrocyanide Industry” is a professional and in-depth research ... Sodium ferrocyanide information, like its definition, classification, ... industry overview. This report covers the international market ... global (such as the US, Europe, Asia, China, ...
(Date:11/21/2014)... , Nov. 20, 2014  Cytori Therapeutics (NASDAQ: ... Hedrick , M.D. will present live at VirtualInvestorConferences.com on December ... TIME:    11:15 am PT / 2:15 pm ET ... into your browser,s address bar: http://bit.ly/1B2KGaL ... receive event updates. This will be a ...
(Date:11/18/2014)... 17, 2014 Cirrascale Corporation ... blade-based and rackmount computing infrastructure, today announced it ... accelerator throughout its GPU-enabled blade server and high-performance ... company’s latest proprietary 80-lane Gen3 PCIe switch-enabled risers, ... Tesla K80 dual-GPU accelerator cards in a single ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... 7 Osteotech, Inc.,(Nasdaq: OSTE ), a ... for,regenerative healing, announced today that its next generation ... MagniFuse(TM) Bone Graft., Robert M. Wynalek, Osteotech,s ... generation bone regeneration products was,developed in response to ...
... (OTC Bulletin Board: BKYI) today announced plans to release third,quarter ... opens. In conjunction with the release, BIO-key has scheduled a,conference ... Friday,November 14, 2008 at 10:00 a.m. Eastern Time., ... Conference ...
... SHANGHAI, China, Nov. 7 /Xinhua-PRNewswire/ -- WuXi ... medical device research,and development outsourcing company with ... today that it has signed a new ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ...
Cached Biology Technology:Osteotech's Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio 2Osteotech's Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio 3BIO-key(R) Announces Third Quarter 2008 Earnings Release and Conference Call Schedule 2WuXi PharmaTech Signs New Collaboration Agreement With Pfizer 2
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
HIV-1 TAT (vN-21)...
Biology Products: